Understanding how to optimize antibiotic dosing for severe pneumonia
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia
['FUNDING_R01'] · MIDWESTERN UNIVERSITY · NIH-10868657
This study is working to make treatments for hospital-acquired pneumonia more effective, especially for patients with antibiotic-resistant infections, by figuring out the best doses of common antibiotics to use based on how each person processes the medication.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MIDWESTERN UNIVERSITY (nih funded) |
| Locations | 1 site (DOWNERS GROVE, UNITED STATES) |
| Trial ID | NIH-10868657 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the treatment of hospital-acquired pneumonia (HAP) caused by antibiotic-resistant bacteria. It aims to develop precision dosing strategies for beta-lactam antibiotics, which are commonly used but often ineffective due to variability in how patients metabolize these drugs, especially in critically ill individuals. By utilizing existing data and samples from a previous research initiative, the study will create robust pharmacokinetic models to better understand how to achieve effective drug levels in patients. This approach seeks to reduce treatment failures and mortality rates associated with HAP.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients diagnosed with hospital-acquired pneumonia caused by antibiotic-resistant pathogens.
Not a fit: Patients with pneumonia not caused by antibiotic-resistant bacteria or those who are not critically ill may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotic treatments for patients suffering from severe pneumonia, potentially reducing mortality rates.
How similar studies have performed: Previous research has shown promise in developing precision dosing strategies for antibiotics, indicating that this approach could be effective.
Where this research is happening
DOWNERS GROVE, UNITED STATES
- MIDWESTERN UNIVERSITY — DOWNERS GROVE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RHODES, NATHANIEL JAMES — MIDWESTERN UNIVERSITY
- Study coordinator: RHODES, NATHANIEL JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.